QPS to Assemble Bioanalysis Lab for Analyzing COVID-19 Clinical-Trial Samples
S is now permitted to import human blood/blood products, other bodily fluids, and tissues that may contain novel coronavirus into its Newark, DE, facility.
QPS, a contract research organization, announced it has assembled an access-restricted bioanalysis lab for analyzing COVID-19 clinical-3trial samples at its facility in Newark, DE.
According to a March 10, 2020 company press release, the US Centers for Disease Control and Prevention’s Department of Health and Human Services granted a permit to QPS enabling the company to import human blood/blood products, other bodily fluids, and tissues that may contain novel coronavirus into its Newark facility.
“In the fight against coronavirus, drug companies need ready access to laboratories equipped to safely manage and analyze samples from ongoing and new clinical trials focused on COVID-19,” said Benjamin Chien, CEO of QPS, in the press release. “We’ve assembled an isolated, restricted access laboratory ready and available to support the life sciences community in determining the safety and efficacy of potential vaccines and treatments for COVID-19 as quickly as possible.”
“Obtaining this permit quickly was a critical step in our business continuity plan and enables QPS to support clients who are urgently working to develop a treatment and/or a vaccine to combat this new coronavirus,” Chien added in the press release. “The scientists in our laboratories have the capability to handle materials contaminated with COVID-19.”
Source: QPS
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
